Department of Pediatrics, Kaiser Permanente Santa Clara Medical Center, Santa Clara, California.
Department of Pediatrics, University of California, San Francisco.
JAMA Pediatr. 2018 Apr 1;172(4):378-385. doi: 10.1001/jamapediatrics.2017.5630.
Treatment of jaundiced newborns with subthreshold phototherapy (phototherapy given to newborns with bilirubin levels below those recommended in American Academy of Pediatrics [AAP] guidelines) is common. However, the use of subthreshold phototherapy may have risks and increase costs, and, to date, it has not been systematically studied in newborns.
To estimate the efficacy of subthreshold phototherapy for newborns with total serum bilirubin (TSB) levels from 0.1 to 3.0 mg/dL below the appropriate AAP phototherapy threshold during the birth hospitalization in preventing readmissions for phototherapy, and to identify predictors of readmission for phototherapy.
DESIGN, SETTING, AND PARTICIPANTS: Retrospective cohort study of 25 895 newborns born at 35 or more weeks' gestation, born in 1 of 16 Kaiser Permanente Northern California hospitals from January 1, 2010, through December 31, 2014, with at least 1 TSB level from 0.1 to 3.0 mg/dL below the appropriate AAP phototherapy threshold and not exceeding the threshold during the birth hospitalization. Data were analyzed from November 1, 2015, to November 28, 2017.
Subthreshold phototherapy during the birth hospitalization.
Readmission for phototherapy.
Among 25 895 newborns with qualifying TSB levels from 0.1 to 3.0 mg/dL below the appropriate AAP phototherapy threshold, 4956 (19.1%) received subthreshold phototherapy and 241 of these (4.9%) were readmitted for phototherapy compared with 2690 of 20 939 untreated newborns (12.8%) (unadjusted odds ratio [OR], 0.35; 95% CI, 0.30-0.40). In a logistic regression model, adjustment for confounding variables, including gestational age, race/ethnicity, formula feedings per day, and the difference between the TSB level and the phototherapy threshold, strengthened the association (OR, 0.28; 95% CI, 0.19-0.40). Estimated numbers needed to treat ranged from 60.8 in the lowest quintile of predicted risk to 6.3 in the highest quintile. Newborns who received formula feedings had lower adjusted odds of readmission for phototherapy compared with exclusively breastfed newborns (OR, 0.58; 95% CI, 0.47-0.72 for >0 to <2 formula feedings per day; OR, 0.24; 95% CI, 0.21-0.27 for ≥6 formula feedings per day). Subthreshold phototherapy was associated with a 22-hour longer length of stay (95% CI, 16-28 hours).
Subthreshold phototherapy during the birth hospitalization is effective in preventing readmissions for phototherapy; however, for each readmission prevented, many newborns require phototherapy who would otherwise not need it.
对胆红素水平低于美国儿科学会(AAP)指南推荐的光疗阈值的新生儿进行亚阈值光疗(给予胆红素水平低于 AAP 光疗阈值的新生儿的光疗)很常见。然而,亚阈值光疗的使用可能存在风险并增加成本,迄今为止,尚未在新生儿中系统研究过。
评估出生住院期间总血清胆红素(TSB)水平低于 AAP 光疗阈值 0.1 至 3.0mg/dL 的新生儿接受亚阈值光疗以预防因光疗而再次入院的效果,并确定再次因光疗而入院的预测因素。
设计、地点和参与者:回顾性队列研究纳入了 2010 年 1 月 1 日至 2014 年 12 月 31 日在加利福尼亚州北部 16 家 Kaiser Permanente 医院出生、胎龄至少为 35 周且至少有一次 TSB 水平低于 AAP 光疗阈值 0.1 至 3.0mg/dL 且在出生住院期间未超过阈值的 25895 名新生儿。数据分析于 2015 年 11 月 1 日至 2017 年 11 月 28 日进行。
出生住院期间的亚阈值光疗。
因光疗而再次入院。
在 25895 名 TSB 水平低于 AAP 光疗阈值 0.1 至 3.0mg/dL 的符合条件的新生儿中,4956 名(19.1%)接受了亚阈值光疗,其中 241 名(4.9%)因光疗而再次入院,而 20939 名未接受治疗的新生儿中(12.8%)有 2690 名(未调整的优势比[OR],0.35;95%CI,0.30-0.40)。在调整了包括胎龄、种族/民族、每天配方奶喂养次数和 TSB 水平与光疗阈值之间的差异等混杂变量的 logistic 回归模型中,这种关联得到了加强(OR,0.28;95%CI,0.19-0.40)。估计的治疗需要人数从风险最低五分位数的 60.8 人到风险最高五分位数的 6.3 人不等。与纯母乳喂养的新生儿相比,接受配方奶喂养的新生儿因光疗而再次入院的调整后优势比更低(OR,0.58;95%CI,0.47-0.72,每天<2 次配方奶;OR,0.24;95%CI,0.21-0.27,每天≥6 次配方奶)。亚阈值光疗与住院时间延长 22 小时(95%CI,16-28 小时)有关。
出生住院期间的亚阈值光疗可有效预防因光疗而再次入院;然而,每预防一次因光疗而再次入院,就会有许多原本不需要光疗的新生儿需要接受光疗。